S'abonner

Tolerogenic signaling by pulmonary CD1c+ dendritic cells induces regulatory T cells in patients with chronic obstructive pulmonary disease by IL-27/IL-10/inducible costimulator ligand - 02/10/14

Doi : 10.1016/j.jaci.2014.05.045 
Maria Tsoumakidou, MD, PhD a, , Sofia Tousa, MD b, Maria Semitekolou, PhD b, Panagiota Panagiotou, MD a, Anna Panagiotou, MD a, , Ioannis Morianos, PhD b, , Eleni Litsiou, PhD a, Aikaterini I. Trochoutsou, MSc b, Maria Konstantinou, MSc c, Konstantinos Potaris, MD, PhD c, Joseph Footitt, MD, PhD d, , Patrick Mallia, MD, PhD d, Spyros Zakynthinos, MD, PhD a, Sebastian L. Johnston, MD, PhD d, Georgina Xanthou, PhD b,
a First Department of Intensive Care Medicine, Evaggelismos Hospital, University of Athens Medical School, Athens, Greece 
b Cellular Immunology Laboratory, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece 
c Thoracic Surgery, Sotiria Chest Hospital, Athens, Greece 
d Airway Disease Infection Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom 

Corresponding author: Georgina Xanthou, PhD, Laboratory of Cellular Immunology, Center for Basic Research Foundation for Biomedical Research of the Academy of Athens, 4, Soranou Efessiou St, Athens 115 27, Greece.Maria Tsoumakidou, MD, PhD, First Department of Intensive Care Medicine, Evaggelismos Hospital, University of Athens Medical School, 45-47 Ipsilantou St, Athens 106 76, Greece.

Abstract

Background

Increased mortality rates in patients with chronic obstructive pulmonary disease (COPD) are largely due to severe infectious exacerbations. Impaired respiratory immunity is linked to the enhanced susceptibility to infections. Dendritic cells (DCs) direct host immune responses toward immunity or tolerance. Pulmonary CD1c+ DCs elicit robust antiviral immune responses in healthy subjects. Nevertheless, their functional specialization in patients with COPD remains unexplored.

Objective

We sought to better understand the mechanisms that suppress respiratory immunity in patients with COPD by examining the immunostimulatory and tolerogenic properties of pulmonary CD1c+ DCs.

Methods

We analyzed the expression of costimulatory and tolerogenic molecules by pulmonary CD1c+ DCs from patients with COPD (CD1c+DCCOPD) and former smokers without COPD. We isolated lung CD1c+ DCs and determined their ability to stimulate allogeneic T-cell responses. The suppressive effects of lung CD1c+ DCs and CD1c+ DC–primed T cells on mixed leukocyte reactions were examined. An experimental human model of COPD exacerbation was used to investigate the levels of critical immunosuppressive molecules in vivo.

Results

CD1c+ DCs from patients with COPD hinder T-cell effector functions and favor the generation of suppressive IL-10–secreting CD4+ T cells that function through IL-10 and TGF-β. IL-27, IL-10, and inducible T-cell costimulator ligand signaling are essential for CD1c+DCCOPD-mediated differentiation of IL-10–producing suppressive T cells. Exposure of lung CD1c+ DCs from nonobstructed subjects to lungs of patients with COPD confers tolerogenic properties. IL-27 and IL-10 levels are increased in the lung microenvironment on rhinovirus-induced COPD exacerbation in vivo.

Conclusion

We identify a novel tolerogenic circuit encompassing suppressive CD1c+ DCs and regulatory T cells in patients with COPD that might be implicated in impaired respiratory immunity and further highlight IL-10 and IL-27 as potent therapeutic targets.

Le texte complet de cet article est disponible en PDF.

Key words : Chronic obstructive pulmonary disease, dendritic cells, regulatory T cells, IL-27, IL-10, inducible costimulator ligand

Abbreviations used : AHR, APC, BAL, CD1c+DCCOPD, CD1c+DCN-Sm, CD1c+DCSM, CFSE, CM, COPD, DC, FOXP3, GAPDH, ICOS, ICOS-L, IL-10R, ILT4, LH, LHCOPD, LHSM, MAF, NE, PD-1, PD-L1, RORC, SLPI, TBX21, TCM, Treg


Plan


 Supported by a research grant from the Hellenic Thoracic Society (to M.T.) and by funds from the First Department of Intensive Care Medicine of Evaggelismos Hospital (to S.Z.). G.X. was supported by the Hellenic Ministries of Health and Education and by the “Romain Pauwels Excellence Award” from the European Respiratory Society. The rhinovirus studies were supported by Medical Research Council Programme Grant G0600879, British Medical Association H.C. Roscoe Fellowships (to J.F. and P.M.), Welcome Trust Grant 083567/Z/07/Z for the Centre for Respiratory Infection, Imperial College and the National Institute for Health Research (NIHR) Biomedical Research Centre funding scheme, the NIHR Clinical Lecturer funding scheme, an unrestricted grant from GlaxoSmithKline, and a grant from Pfizer UK.


© 2014  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 134 - N° 4

P. 944 - octobre 2014 Retour au numéro
Article précédent Article précédent
  • Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency
  • Christopher C. Dvorak, Amel Hassan, Mary A. Slatter, Manfred Hönig, Arjan C. Lankester, Rebecca H. Buckley, Michael A. Pulsipher, Jeffrey H. Davis, Tayfun Güngör, Melissa Gabriel, Jacob H. Bleesing, Nancy Bunin, Petr Sedlacek, James A. Connelly, David F. Crawford, Luigi D. Notarangelo, Sung-Yun Pai, Jake Hassid, Paul Veys, Andrew R. Gennery, Morton J. Cowan
| Article suivant Article suivant
  • Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence
  • Mariya Rozenblit, Mayte Suarez-Farinas, Avner Shemer, Saakshi Khattri, Patricia Gilleaudeau, Mary Sullivan-Whalen, Xiuzhong Zheng, Hui Xu, Irma Cardinale, James G. Krueger, Emma Guttman-Yassky

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.